Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice.
Eight weeks of treatment with rifampin-streptomycin sterilizes Mycobacterium ulcerans infection in mice. Because the bactericidal activity against M. ulcerans of the combination rifampin-moxifloxacin, rifampin-clarithromycin, or moxifloxacin-clarithromycin was similar to that of rifampin-streptomycin, these combinations might be considered as alternative, orally administered combined regimens for treatment of Buruli ulcer in humans.
Ji
Baohong
B
Bacteriologie-Hygiène, Faculté de Médecine Pierre et Marie Curie, Université Paris 6, 91 Boulevard de l'Hôpital, 75634, Paris Cedex 13, France. baohong_ji@yahoo.com
Chauffour
Aurélie
A
Robert
Jérôme
J
Lefrançois
Sébastien
S
Jarlier
Vincent
V
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000904:Antibiotics, Antitubercular / Q000627:therapeutic use; D001372:Aza Compounds / Q000627:therapeutic use; D017291:Clarithromycin / Q000627:therapeutic use; D015169:Colony Count, Microbial; D004338:Drug Combinations; D005260:Female; D024841:Fluoroquinolones; D005528:Foot / Q000382:microbiology; D051379:Mice; D008807:Mice, Inbred BALB C; D000077266:Moxifloxacin; D009165:Mycobacterium Infections, Nontuberculous / Q000188:drug therapy* / Q000382:microbiology; D019911:Mycobacterium ulcerans; D011804:Quinolines / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D013307:Streptomycin / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000904:Antibiotics, Antitubercular; D001372:Aza Compounds; D004338:Drug Combinations; D024841:Fluoroquinolones; D011804:Quinolines; D017291:Clarithromycin; D000077266:Moxifloxacin; D012293:Rifampin; D013307:Streptomycin